Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 9/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262292 | 0.92 | S1PR1 (0.39) | S1PR1S1PR3HDAC4HDAC1HDAC6 | |
| SCHEMBL14285688 | 0.88 | S1PR1 (0.43) | S1PR1S1PR3HDAC4HDAC1HDAC6 | |
| SCHEMBL263501 | 0.87 | S1PR1 (0.37) | S1PR1S1PR3HDAC4HDAC1HDAC6 | |
| SCHEMBL263803 | 0.85 | S1PR1 (0.34) | S1PR1S1PR3FBP1 | |
| SCHEMBL14285686 | 0.84 | S1PR1 (0.43) | S1PR1S1PR3HDAC4HDAC1HDAC6 | |
| SCHEMBL263959 | 0.82 | S1PR1 (0.59) | S1PR1S1PR3 | |
| SCHEMBL2294359 | 0.79 | S1PR1 (0.40) | S1PR1S1PR3KDM4EHPGDALDH1A1 | |
| SCHEMBL3402136 | 0.76 | S1PR1 (0.43) | S1PR1S1PR3NR1H4 | |
| SCHEMBL2288280 | 0.76 | S1PR1 (0.40) | S1PR1S1PR3KDM4EHPGDALDH1A1 | |
| SCHEMBL2544652 | 0.76 | S1PR1 (0.51) | S1PR1S1PR3KDM4EHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101528726-B | Thiophene derivatives as S1P1/EDG1 receptor agonists | ACTELION PHARMACEUTICALS LTD | 2012-11-14 | — | — | CN | disclosed |
| EP-2069322-B1 | THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-8133910-B2 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-13 | — | — | US | disclosed |
| US-8133910-B2 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-13 | — | — | US | disclosed |
| US-8133910-B2 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-13 | — | — | US | disclosed |
| US-20100048648-A1 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048648-A1 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048648-A1 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-25 | — | — | US | disclosed |
| CN-101528726-A | Thiophene derivatives as S1P1/EDG1 receptor agonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-09 | — | — | CN | disclosed |
| EP-2069322-A2 | THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008029306-A2 | THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048648-A1 | Thiophene derivatives as S1P1/EDGE1 receptor agonists | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885HDAC4 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.